UTHR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
United Therapeutics Corp (UTHR) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, solid financial performance, and favorable analyst ratings, making it a compelling choice for long-term growth.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), indicating a positive long-term trend. However, the MACD is negatively expanding (-0.624), and RSI_6 is at 38.604, suggesting the stock is not yet oversold but lacks immediate upward momentum. Key support is at $472.433, and resistance is at $526.823.
Strong Phase 3 ADVANCE OUTCOMES study results for ralinepag, showing a 55% reduction in clinical worsening risk for pulmonary arterial hypertension patients.
Upcoming catalysts include clinical trial data for Idiopathic Pulmonary Fibrosis expected in late March/early April.
Analysts have consistently raised price targets, with UBS setting a high target of $
Promising organ manufacturing and transplant programs, along with new drug delivery innovations like the soft mist inhaler.
Gross margin dropped by 3.10% YoY in Q4 2025, which may indicate cost pressures.
Mixed Q4 results with a revenue miss, though offset by strong EPS growth.
Neutral sentiment from hedge funds and insiders, with no significant trading trends.
In Q4 2025, United Therapeutics reported revenue growth of 7.38% YoY to $790.2M, net income growth of 20.91% YoY to $364.3M, and EPS growth of 23.99% YoY to $7.7. Despite a slight drop in gross margin (-3.10% YoY), the company's financials remain robust and demonstrate strong profitability.
Analysts are overwhelmingly positive on UTHR, with multiple firms raising price targets recently. UBS has a target of $705, Jefferies at $668, and Leerink at $615, all maintaining Buy or Outperform ratings. Analysts highlight the company's strong product pipeline, promising clinical trial results, and strategic innovations as key drivers for future growth.
